![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
SIR-Spheres Y-90 resin microspheres is the first therapeutic radiopharmaceutical approved by the NMPA based on clinical trial data, for the treatment of patients with colorectal cancer liver metastases.
Lead Product(s): Yttrium Radioisotopes
Therapeutic Area: Oncology Product Name: SIR-Spheres Y-90
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022